ATE181328T1 - 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden - Google Patents

5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden

Info

Publication number
ATE181328T1
ATE181328T1 AT96937390T AT96937390T ATE181328T1 AT E181328 T1 ATE181328 T1 AT E181328T1 AT 96937390 T AT96937390 T AT 96937390T AT 96937390 T AT96937390 T AT 96937390T AT E181328 T1 ATE181328 T1 AT E181328T1
Authority
AT
Austria
Prior art keywords
oxadiazole
piperidinyl
phenyl
receptor ligands
derivatives usable
Prior art date
Application number
AT96937390T
Other languages
German (de)
English (en)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Synthelabo filed Critical Synthelabo
Application granted granted Critical
Publication of ATE181328T1 publication Critical patent/ATE181328T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT96937390T 1995-11-09 1996-11-05 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden ATE181328T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE181328T1 true ATE181328T1 (de) 1999-07-15

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937390T ATE181328T1 (de) 1995-11-09 1996-11-05 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden

Country Status (29)

Country Link
US (1) US5929089A (OSRAM)
EP (1) EP0863897B1 (OSRAM)
JP (1) JP4263240B2 (OSRAM)
CN (1) CN1077891C (OSRAM)
AR (1) AR004708A1 (OSRAM)
AT (1) ATE181328T1 (OSRAM)
AU (1) AU707325B2 (OSRAM)
BG (1) BG63463B1 (OSRAM)
BR (1) BR9611311A (OSRAM)
CA (1) CA2236357C (OSRAM)
CO (1) CO4770968A1 (OSRAM)
CZ (1) CZ287268B6 (OSRAM)
DE (1) DE69602970T2 (OSRAM)
EE (1) EE03487B1 (OSRAM)
ES (1) ES2135934T3 (OSRAM)
GR (1) GR3030823T3 (OSRAM)
HU (1) HUP0001168A3 (OSRAM)
IL (1) IL124364A (OSRAM)
MX (1) MX9803696A (OSRAM)
NO (1) NO309606B1 (OSRAM)
NZ (1) NZ321626A (OSRAM)
PL (1) PL186204B1 (OSRAM)
RU (1) RU2167160C2 (OSRAM)
SI (1) SI0863897T1 (OSRAM)
SK (1) SK282335B6 (OSRAM)
TR (1) TR199800827T2 (OSRAM)
TW (1) TW371303B (OSRAM)
UA (1) UA50748C2 (OSRAM)
WO (1) WO1997017345A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
EP0980370A1 (fr) * 1997-05-06 2000-02-23 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
ATE310566T1 (de) 1998-09-18 2005-12-15 Alcon Mfg Ltd 5ht2-agoniste zur behandlung des glaukoms
CN1461216A (zh) * 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
AU5861900A (en) * 1999-06-15 2001-01-02 Respiratorius Ab Receptor agonists and antagonists
WO2002012224A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
WO2002012214A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical Inc. Non-imidazole aryloxyalkylamines as h3 receptor ligands
CA2419036A1 (en) 2000-08-08 2002-02-14 Ortho-Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
EP1434765B1 (en) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7005448B2 (en) 2001-12-14 2006-02-28 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
BRPI0613564A2 (pt) 2005-07-04 2011-01-18 Novo Nordisk As compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
PL1959951T3 (pl) * 2005-12-01 2010-06-30 Hoffmann La Roche Heteroarylo-podstawione pochodne piperydyny jako inhibitory l-cpt1
AU2007267197B2 (en) * 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
MX337721B (es) * 2011-09-19 2016-03-16 Suven Life Sciences Ltd Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
DK0604494T3 (da) * 1991-09-12 1999-11-29 Smithkline Beecham Plc 5-HT4-receptorantagonister
AU667874B2 (en) * 1992-02-06 1996-04-18 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
DE69602970T2 (de) 2000-01-20
TW371303B (en) 1999-10-01
JP4263240B2 (ja) 2009-05-13
DE69602970D1 (de) 1999-07-22
PL186204B1 (pl) 2003-11-28
NO309606B1 (no) 2001-02-26
EE9800155A (et) 1998-12-15
EP0863897A1 (fr) 1998-09-16
AR004708A1 (es) 1999-03-10
CN1077891C (zh) 2002-01-16
SK59998A3 (en) 1998-11-04
CA2236357A1 (en) 1997-05-15
CN1202169A (zh) 1998-12-16
BG102412A (en) 1999-08-31
BR9611311A (pt) 1999-06-29
RU2167160C2 (ru) 2001-05-20
JP2000500125A (ja) 2000-01-11
AU707325B2 (en) 1999-07-08
UA50748C2 (uk) 2002-11-15
CZ287268B6 (en) 2000-10-11
HK1016165A1 (en) 1999-10-29
NO982092L (no) 1998-06-29
IL124364A (en) 2001-08-08
AU7500196A (en) 1997-05-29
BG63463B1 (bg) 2002-02-28
HUP0001168A3 (en) 2001-07-30
CA2236357C (en) 2006-10-17
CZ142198A3 (cs) 1998-08-12
PL326671A1 (en) 1998-10-12
NO982092D0 (no) 1998-05-07
EE03487B1 (et) 2001-08-15
IL124364A0 (en) 1998-12-06
CO4770968A1 (es) 1999-04-30
WO1997017345A1 (fr) 1997-05-15
GR3030823T3 (en) 1999-11-30
EP0863897B1 (fr) 1999-06-16
HUP0001168A2 (hu) 2001-04-28
MX9803696A (es) 1998-09-30
SK282335B6 (sk) 2002-01-07
TR199800827T2 (xx) 1999-02-22
US5929089A (en) 1999-07-27
ES2135934T3 (es) 1999-11-01
NZ321626A (en) 1998-10-28
SI0863897T1 (en) 1999-10-31

Similar Documents

Publication Publication Date Title
ATE181328T1 (de) 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden
DE59810228D1 (de) Phenylalkylderivate mit thrombinhemmender wirkung
BR9804865A (pt) Pesticida 3-(fenil substitu¡do)-5-(tirnil ou furil)-1,2,4-triazÄis
PT1123287E (pt) 1-(piridil substituido)-1,2,4-triazoles insecticidas
FI910503A7 (fi) Nya heterocykliska derivat.
AU1131800A (en) 3-(substituted phenyl)-5-(substituted heterocyclyl)-1,2,4-triazole compounds
FI921925A7 (fi) Kemiluminescerande 3-(substituerad adamant-2-yliden)-1,2-dioxetaner.
ATE206424T1 (de) 5-aryl-3-(8-azabicyclo(3.2.1)oct-3-yl)-1,3,4- oxadiazol-2(3h)-one derivate als 5-ht4 rezeptor liganden
TR200101119T2 (tr) Beyaz sineğe karşı aktiviteye sahip 3-(sübstitüe fenil)-5-tienil-1,2,4-triazol bileşikleri
FI920776A7 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-(substituerad amino)-1,2,4-triazolo-(1,5-a)pyrimidinderivat
ATE205049T1 (de) Potenzierung von dem 2-(thiocyanomethylthio)- benzothiazol-mikrobizid unter verwendung von einer n-alkyl heterocyclischen verbindung
KR960702835A (ko) 헤테로사이클릭 화학(Heterocyclic chemistry)
FI923723L (fi) 4-(4-(4-(-hydroxifenyl)-1-piperazinyl)fenyl)-5-metyl-3h-1,2,4-triazol-3-on derivat
AU1228100A (en) 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
DK0863897T3 (da) Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept
IL88974A0 (en) 5-(substituted-amino)-8-(phenyl or substituted-phenyl)-3h,6h-1,4,5a,8a-tetraazaacenaphthylen-3-ones
ATE252577T1 (de) 3-(3-pyrrolidinyl)-2(3h)-1,3,4- oxadiazolonderivate und ihre verwendung als 5-ht4 liganden
IS5278A (is) 5-(2-Etýl-2H-tetrazól-5-ýl)-1-metýl-1,2,3,6-tetrahýdrópýridín maleat
FR2759699B1 (fr) Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
DE69803654D1 (de) Pestizide 3-(substituiertes phenyl)-5-(thienyl oder furyl)-1,2,4-triazole
FI102533B (fi) 4-(2'-substituoidut etyyli)-1,3-dihydro-2H-indol-2-oniyhdisteet

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification